Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

Pföhler, C; Cree, IA; Ugurel, S; Kuwert, C; Haass, N; Neuber, K; Hengge, U; Corrie, PG; Zutt, M; Tilgen, W; Reinhold, U.
Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Anticancer Drugs. 2003; 14(5):337-340
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Autor/innen der Med Uni Graz:
Ugurel-Becker Selma
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
No effective treatment currently exists for metastatic uveal melanoma. However, recent results obtained by an ATP-based tumor chemosensitivity assay have shown consistent activity of treosulfan+gemcitabine in up to 80% of tumor specimens tested. In this study we describe the first clinical results observed with this drug combination at different European centers in patients with metastatic uveal melanoma. Clinical case series of patients with metastatic uveal melanoma were treated with treosulfan+gemcitabine at seven different centers. Fourteen patients, 13 previously untreated and one pretreated with chemoimmunotherapy, were included in the study. Patients received treosulfan+gemcitabine in four different dose regimens. The response rates, progression-free and overall survival, and toxicity were evaluated. The analysis of 14 patients revealed one complete response, three partial responses and a stable disease in eight cases. The objective response rate was 28.6%, the median overall survival was 61 weeks [95% confidence interval (CI) 54-133 weeks], the progression-free survival was 28.5 weeks (95% CI 13-62 weeks) and the 1-year survival rate was 80%. The drugs were well tolerated. The most common side-effects were leuko- and thrombocytopenia. These preliminary results suggest potential therapeutic benefit of treosulfan+gemcitabine treatment in metastatic uveal melanoma and warrant further controlled studies.
Find related publications in this database (using NLM MeSH Indexing)
Aged -
Antimetabolites, Antineoplastic - administration and dosage
Antineoplastic Agents, Alkylating - administration and dosage
Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Busulfan - administration and dosage Busulfan - analogs and derivatives
Deoxycytidine - administration and dosage Deoxycytidine - analogs and derivatives
Disease Progression -
Feasibility Studies -
Female -
Hematologic Diseases - chemically induced Hematologic Diseases - epidemiology
Humans -
Male -
Melanoma - drug therapy
Middle Aged -
Pilot Projects -
Survival Analysis -
Uveal Neoplasms - drug therapy

Find related publications in this database (Keywords)
chemotherapy
choroidal melanoma
gemcitabine
treosulfan
© Meduni Graz Impressum